Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Founded in San Diego, California in 2008, Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Samumed or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.